Patents Examined by Brad Duffy
  • Compositions and methods related to recombinant antibodies to histone posttranslational modifications
    Patent number: 10208110
    Abstract: Embodiments concern compositions and methods involving recombinant antibodies to histone post-translational modifications. The invention provides compositions and methods for histone methyltransferase assays. In certain embodiments, the compositions and methods involve a recombinant antibody that binds histone H3 fragment harboring biomarkers such as H3K9me3 mark, H3K4me3 mark, H3K36me3 mark, H3K27me3, H3K9me3 and H3S10phos or a recombinant antibody that binds histone H4 fragment harboring H4K20me3 mark.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 19, 2019
    Assignee: The University of Chicago
    Inventors: Takamitsu Hattori, Shohei Koide, Joseph Taft, Akiko Koide
  • CD37-binding molecules and immunoconjugates thereof
    Patent number: 10202460
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 12, 2019
    Assignee: Debiopharm International, S.A.
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • Functionalized microgels with fibrin binding elements
    Patent number: 10195304
    Abstract: Ultra-low crosslinked microgels made of an ultra-low crosslinked polymer are provided. The microgels, also referred to as Platelet-like Particles (PLPs), preferably have <0.5% crosslinking densities. One or more of the polymers are conjugated with a fibrin-binding element or moiety, preferably H6, in an amount effective to confer to the microgel selective binding to fibrin under physiological conditions. The PLPs can recapitulate multiple key functions of platelets including binding, stabilizing and enhancing fibrin clot formation, responsiveness to injury cues, and induction of clot contraction. In a preferred embodiment, the microgel or PLP has little or no binding to soluble fibrinogen under physiological conditions compared to its binding to fibrin. The microgels or PLPs are prepared using crosslinker-free synthesis conditions, and can promote or induce clotting and clot contraction.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: February 5, 2019
    Assignee: Georgia Tech Research Corporation
    Inventors: Thomas H. Barker, Ashley Carson Brown, Louis Andrew Lyon, Sarah E. Stabenfeldt, Nicole Welsch
  • Anti-HER3 antibodies and uses thereof
    Patent number: 10196456
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: February 5, 2019
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Proteomic identification of antibodies
    Patent number: 10175249
    Abstract: Methods and compositions for identification of candidate antigen-specific variable regions as well as generation of antibodies or antigen-binding fragments that could have desired antigen specificity are provided. For example, in certain aspects, methods for determining amino acid sequences of serum antibody CDR3 and abundancy levels are described. In some aspects, methods for determining nucleic acid sequences of antibody variable region sequences and the frequency thereof in biological samples are provided. Furthermore, the invention provides methods for identification and generation of antibodies or antigen-binding fragments that comprise highly-represented CDR domains.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 8, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jason Lavinder, Daniel Boutz, Yariv Wine, Edward M. Marcotte, George Georgiou
  • High affinity anti-GD2 antibodies
    Patent number: 10167341
    Abstract: In this application are described high affinity anti-GD2 antibody agents, and various methods and reagents related thereto, including for example for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 1, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Mahiuddin Ahmed, Qi Zhao
  • Cytotoxic immunoglobulin
    Patent number: 10125197
    Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 60 kD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: November 13, 2018
    Assignee: F-STAR BIOTECHNOLOGISCHE FORSCHUNGS-UND ENTWICKLUNGSGES.M.B.H
    Inventors: Gottfried Himmler, Geert Mudde, Anton Bauer, Gerda Redl, Maximillian Woisetschlager
  • Dual specificity antibody fusions
    Patent number: 10100130
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: October 16, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Covalent diabodies and uses thereof
    Patent number: 10093739
    Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: October 9, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Covalent diabodies and uses thereof
    Patent number: 10093738
    Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: October 9, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Anti P2X7 receptor antibodies and fragments thereof
    Patent number: 10053508
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: August 21, 2018
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Antibody variants composition
    Patent number: 10040861
    Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 7, 2018
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Rinpei Niwa, Mami Tsuchiya
  • Humanized anti-TF-antigen antibodies
    Patent number: 10023651
    Abstract: Provided are humanized monoclonal antibodies (mAbs) or fragments thereof that bind with specificity to the Thomsen-Friedenreich (TF) human tumor antigen. Three distinct variable heavy and three variable light chains are provided, and can be combined to make a total of twenty-five distinct heavy and light chain combinations. Methods of using the mAbs and fragments thereof for cancer therapy and diagnostic imaging are provided, as are methods for making the mAbs and fragments thereof. In vitro cell cultures that express the mAbs and fragments thereof, and kits are also provided.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: July 17, 2018
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Kate Rittenhouse-Olson, Julia Abdullah, Jing Ying Eng, Stephen T. Koury
  • Neutralizing molecules to influenza viruses
    Patent number: 10017561
    Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: July 10, 2018
    Assignee: I2 PHARMACEUTICALS, INC.
    Inventors: Lawrence Horowitz, Ramesh Bhatt, Arun Kashyap
  • Acceptor framework for CDR grafting
    Patent number: 9994645
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: June 12, 2018
    Assignee: ESBATech—a Novartis Company LLC
    Inventor: Dominik Escher
  • SEZ6 modulators and methods of use
    Patent number: 9993566
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: June 12, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: David Liu, Deepti Rokkam, Sheila Bheddah, Javier Lopez-Molina, Laura Saunders
  • Anti-IFNAR1 antibodies with reduced Fc ligand affinity
    Patent number: 9988459
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: June 5, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Pharmaceutical compositions with resistance to soluble CEA
    Patent number: 9982063
    Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: May 29, 2018
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Ralf Lutterbüse, Petra Fluhr, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
  • Human monoclonal antibody human CD134 (OX40) and methods of making and using same
    Patent number: 9969810
    Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 15, 2018
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Shinichiro Kato, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
  • Covalent diabodies and uses thereof
    Patent number: 9963510
    Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: May 8, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang